Regulatory approval
Published by the Health Service Executive.
The Republic of Ireland's Health Service Executive (HSE) has approved brentuximab vedotin in combination with ESHAP (etoposide, cisplatin, and cytarabine) for reimbursement as a treatment option for the treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma.
This is written in the approval document as:
Treatment of adult patients with relapsed/refractory CD30+ Hodgkin's lymphoma
Citation
Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2019, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdfTherapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab Vedotin, Cisplatin, Cytarabine, Etoposide |